Clinical trial · no report yet · Phase 2/Phase 3
PCS IX
Management of Castration-Resistant Prostate Cancer with Oligometastases
- NCT02685397 ↗
- Active, not recruiting
- Sir Mortimer B. Davis - Jewish General Hospital
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: an Adaptive Phase II/III Randomized Trial.
- Phase
- Phase 2/Phase 3
- Status
- Active, not recruiting
- Conditions
- Castration-resistant Prostate Cancer Patients with Oligometastases
- Interventions
- Leuprolide Acetate; Goserelin Acetate; Triptorelin; Enzalutamide; Stereotactic Body Radiation Therapy
- Arms
- LHRH agonist + Enzalutamide · Active comparator
- LHRH agonist + Enzalutamide + SBRT · Experimental
- Enrollment
- 102
- Primary outcomes
- Radiographic Progression-free Survival
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
- Start
- Oct 2016
- Primary completion
- Apr 2027 (estimated)
- Results posted
- No
- Registry record
- NCT02685397 · updated Dec 4, 2024
Publications
linked from the registry- Niazi T, Saad F, Tisseverasinghe S, Koul R, Thibault I, Chung PWM, Wakil G, Lock M, Delouya G, Bahoric B, Feifer A, Agnihotram VR, Tsakiridis T, Cury FL, Dahmane R, Patil NG, Tyldesley S. Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025 Sep;26(9):1158-1167. doi: 10.1016/S1470-2045(25)00351-1. PubMed 40907514